Johnson & Johnson (JNJ): Price and Financial Metrics
Johnson & Johnson (JNJ)
Today's Latest Price: $149.18 USD
Updated Sep 18 7:00pm
Add JNJ to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 232 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
JNJ Stock Summary
- Johnson & Johnson's market capitalization of $392,764,606,000 is ahead of 99.77% of US-listed equities.
- Johnson & Johnson's stock had its IPO on January 1, 1986, making it an older stock than 92.88% of US equities in our set.
- The volatility of Johnson & Johnson's share price is greater than that of only 0.56% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to JNJ, based on their financial statements, market capitalization, and price volatility, are WMT, TSM, PG, MA, and TSLA.
- JNJ's SEC filings can be seen here. And to visit Johnson & Johnson's official web site, go to www.jnj.com.
JNJ Stock Price Chart Technical Analysis Charts
JNJ Price/Volume Stats
| Current price | $149.18 | 52-week high | $157.00 |
| Prev. close | $147.17 | 52-week low | $109.16 |
| Day low | $146.20 | Volume | 12,174,044 |
| Day high | $149.65 | Avg. volume | 8,458,481 |
| 50-day MA | $149.00 | Dividend yield | 2.71% |
| 200-day MA | $144.99 | Market Cap | 392.76B |
Johnson & Johnson (JNJ) Company Bio
Johnson & Johnson researches and develops, manufactures, and sells various products in the health-care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Some of its well-known brands include Tylenol-fever, Listerine-bad breath, Splenda-no-calorie sweetener, Neutrogena-skin care, Pepcid-heartburn, Zyrtec - allergy, Motrin-ibuprofen, Sudafed-allergy, and plenty more. The company was founded in 1885 and is based in New Brunswick, New Jersey.
JNJ Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $149.18 | $63.43 | -57% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Johnson & Johnson. To summarize, we found that Johnson & Johnson ranked in the 27th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Johnson & Johnson, consider:
- In the past 5.74 years, Johnson & Johnson has a compound free cash flow growth rate of 0.03%; that's higher than merely 24.14% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately just 18.2% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- JNJ's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 41.02% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -58% |
| 1% | -57% |
| 2% | -57% |
| 3% | -56% |
| 4% | -56% |
| 5% | -56% |
HAPP, XRAY, CPIX, WAT, and HOLX can be thought of as valuation peers to JNJ, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...